Episode
Charting the Course of ALL: From Diagnosis to Advances
- Podcast
- Treating Blood Cancers
- Published
- Jul 9, 2025
- Duration seconds
- 2206
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/charting-the-course-of-all-from-diagnosis-to-advances/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/treating-blood-cancers-14318/charting-the-course-of-all-from-diagnosis-to-advances.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA Recorded on June 27, 2025 Catherine Lai, MD, MPH Associate Professor Physician Leader, Leukemia Clinical Research Unit University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, PA In this episode, Dr. Catherine Lai, from the University of Pennsylvania’s Perelman Center for Advanced Medicine, joins us to discuss the current landscape of adult acute lymphoblastic leukemia (ALL) treatment. She highlights recent advances in frontline and relapsed therapies, the critical role of measurable residual disease (MRD), and the use of immunotherapy and targeted treatments. Dr. Lai further explores transplant considerations, management of side effects, and tailored approaches for B-cell and T-cell ALL. She also emphasizes patient-centered care, including strategies for end-of-life discussions and shared decision-making. Tune in today for expert insights and practical takeaways on the evolving future of ALL care!